Literature DB >> 28786422

Prostate cancer: The influence of steroid metabolism on CYP17A1 inhibitor activity.

Frank Claessens1, Lisa Moris2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28786422     DOI： 10.1038/nrurol.2017.132

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  10 in total

Review 1.  Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer.

Authors:  Gerhardt Attard; Arie S Belldegrun; Johann S de Bono
Journal:  BJU Int       Date:  2005-12       Impact factor: 5.588

2.  Measurement of a Comprehensive Sex Steroid Profile in Rodent Serum by High-Sensitive Gas Chromatography-Tandem Mass Spectrometry.

Authors:  Maria E Nilsson; Liesbeth Vandenput; Åsa Tivesten; Anna-Karin Norlén; Marie K Lagerquist; Sara H Windahl; Anna E Börjesson; Helen H Farman; Matti Poutanen; Anna Benrick; Manuel Maliqueo; Elisabet Stener-Victorin; Henrik Ryberg; Claes Ohlsson
Journal:  Endocrinology       Date:  2015-04-09       Impact factor: 4.736

3.  Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.

Authors:  Venkatesh D Handratta; Tadas S Vasaitis; Vincent C O Njar; Lalji K Gediya; Ritesh Kataria; Pankaj Chopra; Donnell Newman; Rena Farquhar; Zhiyong Guo; Yun Qiu; Angela M H Brodie
Journal:  J Med Chem       Date:  2005-04-21       Impact factor: 7.446

4.  Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.

Authors:  Nicholas D James; Johann S de Bono; Melissa R Spears; Noel W Clarke; Malcolm D Mason; David P Dearnaley; Alastair W S Ritchie; Claire L Amos; Clare Gilson; Rob J Jones; David Matheson; Robin Millman; Gerhardt Attard; Simon Chowdhury; William R Cross; Silke Gillessen; Christopher C Parker; J Martin Russell; Dominik R Berthold; Chris Brawley; Fawzi Adab; San Aung; Alison J Birtle; Jo Bowen; Susannah Brock; Prabir Chakraborti; Catherine Ferguson; Joanna Gale; Emma Gray; Mohan Hingorani; Peter J Hoskin; Jason F Lester; Zafar I Malik; Fiona McKinna; Neil McPhail; Julian Money-Kyrle; Joe O'Sullivan; Omi Parikh; Andrew Protheroe; Angus Robinson; Narayanan N Srihari; Carys Thomas; John Wagstaff; James Wylie; Anjali Zarkar; Mahesh K B Parmar; Matthew R Sydes
Journal:  N Engl J Med       Date:  2017-06-03       Impact factor: 91.245

5.  Steroidogenic Metabolism of Galeterone Reveals a Diversity of Biochemical Activities.

Authors:  Mohammad Alyamani; Zhenfei Li; Michael Berk; Jianneng Li; Jingjie Tang; Sunil Upadhyay; Richard J Auchus; Nima Sharifi
Journal:  Cell Chem Biol       Date:  2017-06-22       Impact factor: 8.116

6.  Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor.

Authors:  Ziyang Yu; Changmeng Cai; Shuai Gao; Nicholas I Simon; Howard C Shen; Steven P Balk
Journal:  Clin Cancer Res       Date:  2014-05-29       Impact factor: 12.531

Review 7.  CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents.

Authors:  Lina Yin; Qingzhong Hu
Journal:  Nat Rev Urol       Date:  2013-11-26       Impact factor: 14.432

8.  Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer.

Authors:  Zhenfei Li; Andrew C Bishop; Mohammad Alyamani; Jorge A Garcia; Robert Dreicer; Dustin Bunch; Jiayan Liu; Sunil K Upadhyay; Richard J Auchus; Nima Sharifi
Journal:  Nature       Date:  2015-06-01       Impact factor: 49.962

9.  Sex hormone-binding globulin regulation of androgen bioactivity in vivo: validation of the free hormone hypothesis.

Authors:  Michaël R Laurent; Geoffrey L Hammond; Marco Blokland; Ferran Jardí; Leen Antonio; Vanessa Dubois; Rougin Khalil; Saskia S Sterk; Evelien Gielen; Brigitte Decallonne; Geert Carmeliet; Jean-Marc Kaufman; Tom Fiers; Ilpo T Huhtaniemi; Dirk Vanderschueren; Frank Claessens
Journal:  Sci Rep       Date:  2016-10-17       Impact factor: 4.379

10.  Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy.

Authors:  Zhenfei Li; Mohammad Alyamani; Jianneng Li; Kevin Rogacki; Mohamed Abazeed; Sunil K Upadhyay; Steven P Balk; Mary-Ellen Taplin; Richard J Auchus; Nima Sharifi
Journal:  Nature       Date:  2016-05-26       Impact factor: 49.962
  10 in total
  1 in total

1.  HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer.

Authors:  Mohammad Alyamani; Hamid Emamekhoo; Sunho Park; Jennifer Taylor; Nima Almassi; Sunil Upadhyay; Allison Tyler; Michael P Berk; Bo Hu; Tae Hyun Hwang; William Douglas Figg; Cody J Peer; Caly Chien; Vadim S Koshkin; Prateek Mendiratta; Petros Grivas; Brian Rini; Jorge Garcia; Richard J Auchus; Nima Sharifi
Journal:  J Clin Invest       Date:  2018-06-25       Impact factor: 14.808
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.